announcements & circulars-凯发88
english
凯发88-凯发vip-娱乐凯发app下载
中文繁体
company
overview
board of directors
scientific advisory board
partnering
core competence
technology
bispecific
mix-mab
biologics manufacturing
publications
pipeline
overview
envafolimab(kn035)
kn046
kn026
kn026 kn046
kn019
investors
information disclosure
corporate governance
stock information
ir contacts
email subscription
news
press release
media report
career
corporate culture
job opportunities
contact us
company
overview
board of directors
scientific advisory board
partnering
core competence
technology
bispecific
mix-mab
biologics manufacturing
publications
pipeline
overview
envafolimab(kn035)
kn046
kn026
kn026 kn046
kn019
investors
information disclosure
corporate governance
stock information
ir contacts
email subscription
news
press release
media report
career
corporate culture
job opportunities
contact us
english
凯发88-凯发vip-娱乐凯发app下载
中文繁体
investors
information disclosure
listing documents
financial reports
announcements & circulars
company presentation
corporate governance
stock information
ir contacts
email subscription
announcements & circulars
the announcement begins in december 2019
voluntary announcement - first patient dosed in a phase ii clinical trial of kn019 for rheumatoid arthritis treatment in china
2019-12-16
terms of reference of the strategy committee
2019-12-11
terms of reference of the remuneration committee
2019-12-11
terms of reference of the audit committee
2019-12-11
terms of reference of the nomination committee
2019-12-11
amended and restated memorandum of association
2019-12-11
list of directors and their role and function
2019-12-11
announcement of offer price and allotment results
2019-12-11
global offering-formal notice
2019-12-02
8
9
10
11
prev
11/11
网站地图
